Chonluten
RecoveryPreclinicalAlso known as: Pulmonary peptide
Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function.
Overview
At A Glance
Mechanism of Action…
Mechanism of Action
Mechanism of Action
Chonluten's proposed mechanism differs depending on which form is under discussion, but all three variants (polypeptide extract, synthetic EDG tripeptide, and by extension the related AEDP tetrapeptide Bronchogen) fall within the Khavinson short-peptide bioregulator framework.
Polypeptide extract form (historical Chonluten)
The bovine/porcine bronchial polypeptide extract is an undefined mixture of low-molecular-weight peptides prepared by aqueous extraction of bronchial mucosa followed by ultrafiltration or gel filtration. Molecular weight range is typically reported as 1,000–10,000 daltons. The proposed mechanism is tissue-derived bioregulator signalling — that animal-tissue-derived peptide mixtures retain tissue-specific regulatory information that can guide homologous tissue regeneration in recipient organisms. This framework is mechanistically vague by modern pharmacology standards. It predates the era in which individual bioactive components can be identified and characterised. Chonluten extract cannot be described with molecular specificity because its composition is not defined.
Synthetic EDG tripeptide (later Chonluten formulation)
At approximately 319 daltons (H-Glu-Asp-Gly-OH), the synthetic tripeptide is small enough to cross membranes passively. The Khavinson framework proposes that EDG enters bronchial epithelial cells, diffuses into nuclei, and makes sequence-selective contacts with exposed DNA regions and histone tails, producing preferential upregulation of respiratory-epithelial survival and regeneration programmes — ciliogenesis, mucin transcription, surfactant production, anti-inflammatory programmes.
Three mechanistic layers in the Khavinson framework:
1. Passive membrane permeation. EDG is sufficiently small and polar to cross phospholipid bilayers. Tritiated-peptide biodistribution in rodents reports lung uptake after intraperitoneal or oral administration, with radiolabel recovered in multiple tissues. Intact-peptide versus catabolite distinction is not made in the available data.
2. Nuclear import. Passive diffusion through nuclear pores is assumed. No karyopherin-mediated import is invoked. At 319 daltons, nuclear pore passage is plausible.
3. Chromatin modulation. Sequence-selective contacts with DNA and histone tails produce tissue-appropriate gene expression changes. This is the framework-level claim; it is not validated by modern chromatin biology methods (ChIP-seq, ATAC-seq, CUT&RUN) in any Khavinson peptide.
Relation to Bronchogen (AEDP)
Bronchogen is the closely-related tetrapeptide (Ala-Glu-Asp-Pro, AEDP) in the same respiratory-bioregulator class. Khavinson positions EDG Chonluten and AEDP Bronchogen as related but distinct sequences with possibly different preferred chromatin targets. The supporting data for differential targeting are not available in modern form.
Alternative conservative framing
A parsimonious interpretation treats Chonluten EDG as a glutamate-aspartate-glycine tripeptide delivering three amino acids in rapidly-absorbed short-peptide form. Biological effects could reflect substrate delivery, non-specific amino-acid signalling (glutamate as an excitatory signal, glycine as an inhibitory neurotransmitter and glutathione precursor), or non-specific nutritional support to stressed respiratory tissue. Under this framing, any equivalent amino-acid delivery would produce similar effects.
Polypeptide extract alternative framing
The polypeptide extract form contains unknown bioactive components. Any mechanistic claim about the extract must acknowledge that (a) individual active components are not isolated or characterised, (b) batch-to-batch variation is uncontrolled, and (c) modern pharmacology requires defined composition for mechanism attribution. The extract might contain biologically active peptides; it might also contain predominantly inert material with minimal bioactivity. Without defined composition, the mechanistic claim is untestable.
Receptor pharmacology
No GPCR, nuclear receptor, or defined enzyme target identified for Chonluten in either form. It does not engage β-adrenoceptors (bronchodilator targets), muscarinic receptors (anticholinergic bronchodilator targets), glucocorticoid receptors (inhaled corticosteroid targets), or known inflammatory signalling nodes (IL-5, IL-13, TSLP — biologic therapy targets). The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class.
Compared to evidence-graded respiratory pharmacology
Inhaled β2-agonists cause bronchodilation via structurally characterised receptor activation with minute-level kinetics. Inhaled corticosteroids suppress eosinophilic inflammation via glucocorticoid receptor activation with decades of RCT validation. Long-acting muscarinic antagonists block parasympathetic bronchoconstriction with mapped receptor kinetics. Biologics block specific cytokines (IL-5, IL-4/13, TSLP) with validated mechanism and registered indications. Chonluten sits at a completely different mechanism-specification level — framework-level hypothesis rather than measured pharmacology.
Overview
Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "bronchial bioregulator" intended to support respiratory epithelium, alveolar function, and airway regeneration in chronic obstructive pulmonary disease (COPD), chronic bronchitis, post-infectious respiratory dysfunction, and age-related decline of pulmonary function. Historically Chonluten has been marketed in two overlapping forms: (1) as a polypeptide extract prepared from bovine or porcine bronchial mucosa — an undefined-mixture "natural bioregulator" — and (2) as a defined-sequence synthetic short peptide, most commonly cited as the tripeptide Glu-Asp-Gly (EDG) in later Khavinson publications, sometimes rendered H-Glu-Asp-Gly-OH or E-D-G. Chonluten is closely related to Bronchogen, which Khavinson's group developed as the longer tetrapeptide (Ala-Glu-Asp-Pro / AEDP) synthetic alternative in the same respiratory-bioregulator class, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Cardiogen, and Cartalax within the broader Khavinson peptide-bioregulator programme.
Outside Russia and a small number of former-Soviet-state publications, Chonluten is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in GOLD, ATS/ERS, or NICE guidelines for COPD or chronic bronchitis. Published Russian work — most of it authored by Khavinson and collaborators — comprises in vitro studies in bronchial epithelial cell culture, rodent lung injury experiments, and small uncontrolled observational case series in elderly COPD and chronic bronchitis patients (Khavinson et al., 2011; Chalisova et al., 2015; Anisimov et al., 2010).
The relationship between Chonluten and Bronchogen deserves clear description. Both are positioned as respiratory bioregulators within the Khavinson framework. Chonluten in polypeptide-extract form was the original bronchial bioregulator — an undefined mixture from animal tissue, prepared by the extraction methodology Khavinson developed in the 1970s and 1980s. Bronchogen (AEDP) was subsequently synthesised as a defined tetrapeptide intended to reproduce the extract's biological activity in chemically characterised form. Chonluten in short-peptide form (EDG) represents a further minimisation to three amino acids, testing whether an even shorter sequence retains bioregulator activity. All three products — Chonluten extract, Chonluten-EDG, and Bronchogen-AEDP — are sold in the post-Soviet supplement market with overlapping positioning.
BodyHackGuide covers Chonluten because it is sold online as both oral capsule (typically 20 mg with undisclosed active content) and injectable forms, and because it appears in longevity-stack discussions as a respiratory-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded respiratory support toward the interventions with substantial replication: smoking cessation (by far the single highest-impact intervention), pulmonary rehabilitation, inhaled short- and long-acting bronchodilators for obstructive disease, inhaled corticosteroids where indicated, vaccinations (influenza, pneumococcal, COVID-19, RSV in older adults), weight management for restrictive/obesity-related disease, and specific biologic therapy (benralizumab, mepolizumab, dupilumab, tezepelumab) for severe asthma phenotypes. Chonluten is a plausible hypothesis within the Khavinson framework. It is not, in 2026, an evidence-graded respiratory therapy.
Chemical Information
IUPAC Name
L-Alanyl-L-glutamyl-L-aspartylglycine
CAS Number
70381-80-5
Molecular Formula
H-Ala-Glu-Asp-Gly-OH
Molecular Mass
402.37 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Contraindications
Absolute contraindications
- Pregnancy — no reproductive toxicology data
- Breastfeeding — no excretion/infant safety data
- Paediatric use (<18)
- Active lung cancer or recent history
- Active tuberculosis — specific anti-TB therapy required
- Acute pneumonia or bacterial exacerbation — appropriate antibiotic therapy required
- Known hypersensitivity to Chonluten, any Khavinson bioregulator, or bovine/porcine protein (for extract form)
- Prion disease history or concern (extract form)
Relative contraindications (supervised use only)
- Severe COPD (GOLD 3–4, FEV1 <50%)
- Pulmonary fibrosis — evidence-graded antifibrotic therapy (nintedanib, pirfenidone)
- Pulmonary hypertension
- Home oxygen therapy
- Severe asthma on biologics
- Recent solid organ transplant
- Severe renal impairment (eGFR <30)
- Decompensated hepatic disease
Use with caution
- Animal protein allergy (beef, pork) — avoid extract form, synthetic EDG may be appropriate
- Multiple respiratory medications (polypharmacy)
- Active smoker — Chonluten does not substitute for cessation
- Occupational lung disease
Quality-of-supply contraindication
Do not use Chonluten from vendors without third-party testing. For extract form, pathogen screening and sourcing documentation required.
Symptoms requiring evaluation, not bioregulators
New dyspnoea, haemoptysis, unexplained weight loss, night sweats, persistent cough over 3 weeks, fever, chest pain — prompt medical evaluation, not self-treatment.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Chonluten.
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
View Full Dosage Guide →
Protocols, calculator & safety for Chonluten
Research Score
1 PubMed studies
Quality Indicators
Data Completeness
88%Research Credibility
Limited research available
Quick Facts
Molecular Weight
402.37 g/mol
CAS Number
70381-80-5
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Chonluten and what is it claimed to do?
Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute, marketed in two overlapping forms: (1) a polypeptide extract prepared from bovine or porcine bronchial mucosa, and (2) a defined-sequence synthetic short peptide, most commonly Glu-Asp-Gly (EDG). It is positioned as support for bronchial epithelium, alveolar function, and airway regeneration in COPD, chronic bronchitis, and post-infectious respiratory dysfunction. Russian literature reports in vitro bronchial epithelial effects and small uncontrolled observational series in elderly respiratory patients (Chalisova et al., 2015; Khavinson et al., 2011). Not FDA/EMA-approved, not in any respiratory guideline. Treat as experimental.
How is Chonluten different from Bronchogen?
Both are respiratory bioregulators in the Khavinson framework. Chonluten was the original — either a bovine/porcine bronchial polypeptide extract or the synthetic Glu-Asp-Gly tripeptide. Bronchogen is the tetrapeptide Ala-Glu-Asp-Pro (AEDP) synthesised as a defined-sequence alternative in the same respiratory bioregulator class. Bronchogen has slightly more in vitro and rodent data in English-indexed literature. Community users sometimes stack both or alternate between them; there is no head-to-head evidence establishing which is superior. If budget-constrained, pick one rather than running both simultaneously.
Does Chonluten actually help with COPD or chronic bronchitis?
Honest answer: the evidence is thin. Russian uncontrolled observational series report subjective improvement and modest spirometry changes after 20–30 day oral cycles. No placebo-controlled RCTs exist. No head-to-head comparison with inhaled bronchodilators, ICS, or biologics. For COPD and chronic bronchitis, evidence-graded first-line is smoking cessation, inhaled bronchodilators, ICS where indicated, pulmonary rehabilitation, vaccinations, and specific biologic therapy for severe asthma phenotypes. Chonluten is a speculative adjunct, not a substitute.
What is the correct Chonluten dose?
Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, 60–90 day washouts. 20 mg capsule contains undisclosed actual active content (historically 2–4 mg peptide or peptide-fraction for extract forms). For synthetic EDG subcutaneous, 2–5 mg daily for 10 days. Autumn entry before winter respiratory season is Russian clinical convention. No dose-ranging trial has established that 20 mg is optimal.
Is Chonluten safe?
Short-term safety signal from Russian literature is mild — occasional nausea, mild headache, rare rash. Extract form has slightly higher allergic reaction rate, likely reflecting bovine/porcine protein recognition. Animal protein allergy is a contraindication for extract form. Pregnancy, breastfeeding, paediatric use, active lung cancer, active TB, and acute respiratory infections are absolute contraindications. Use third-party verified product. For extract form, ensure pathogen screening and sourcing documentation.
Should I use Chonluten extract or synthetic EDG tripeptide?
The synthetic EDG tripeptide is the cleaner choice — chemically defined, no animal protein, lower allergic-reaction risk, no prion-disease concern. The polypeptide extract is the historical form and some users prefer it based on the argument that the undefined mixture contains bioactivity not captured by the minimised synthetic sequence. This argument is theoretical. For users with any animal-protein allergy, the synthetic EDG form is clearly preferable. For users prioritising modern pharmaceutical quality standards, the synthetic form is preferable. The extract form has historical precedent but fewer modern quality advantages.
Can I use Chonluten with inhaled bronchodilators or corticosteroids?
Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions between Chonluten and inhaled β2-agonists, muscarinic antagonists, or corticosteroids. The inhaled drugs act locally with minimal systemic exposure. Continue inhaled maintenance therapy during Chonluten cycles — do not substitute Chonluten for inhalers. Notify your pulmonologist of bioregulator cycles.
How does Chonluten compare to other Khavinson peptides?
Chonluten is one of two Khavinson respiratory bioregulators — the other being Bronchogen (AEDP tetrapeptide). Chonluten historically preceded Bronchogen as the bovine-bronchial extract, and Glu-Asp-Gly emerged as a proposed defined-sequence active component. Within the broader Khavinson family (Epitalon, Pinealon, Thymogen, Vilon, Livagen, Cardiogen, Cartalax), Chonluten occupies the respiratory niche alongside Bronchogen. Evidence base is smaller than for Epitalon (most-studied) or Thymogen (most regulatory recognition).
Where do I source quality Chonluten?
Supply channels: post-Soviet supplement vendors (20 mg oral capsules, both extract and synthetic forms available), and international research-peptide suppliers (lyophilised synthetic EDG). For extract form, require pathogen screening documentation and bovine/porcine source transparency. For synthetic form, require third-party HPLC peptide content confirmation and endotoxin testing. Avoid vendors without certificates of analysis. Higher verified-quality product is worth the cost premium — this is particularly true for the extract form given animal-tissue origin.
If I have respiratory issues and see a BodyHackGuide ad, what is the actual priority list?
For respiratory health through BodyHackGuide ad funnel, evidence-graded ranked: (1) smoking cessation if applicable — nothing else matters nearly as much; (2) pulmonary rehabilitation and structured exercise; (3) vaccinations (influenza, pneumococcal, COVID-19, RSV); (4) clinician-prescribed inhaled therapy for obstructive disease; (5) NAC 600–1200 mg daily for chronic bronchitis; (6) environmental air quality and allergen reduction; (7) evidence-based biologics for severe asthma phenotypes; (8) weight management for obesity-related disease; (9) experimental bioregulators like Chonluten, Bronchogen as advanced-protocol tier-9 add-ons. Use ads to capture respiratory-interested traffic, convert to evidence-graded content, offer Chonluten only to users who have exhausted proven options.
Research Tools
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.